NO983453L - Fremgangsmåte for ökning av sfinkterfunksjon - Google Patents

Fremgangsmåte for ökning av sfinkterfunksjon

Info

Publication number
NO983453L
NO983453L NO983453A NO983453A NO983453L NO 983453 L NO983453 L NO 983453L NO 983453 A NO983453 A NO 983453A NO 983453 A NO983453 A NO 983453A NO 983453 L NO983453 L NO 983453L
Authority
NO
Norway
Prior art keywords
procedures
human
compound
formula
effective amount
Prior art date
Application number
NO983453A
Other languages
English (en)
Norwegian (no)
Other versions
NO983453D0 (no
Inventor
George Joseph Cullinan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603147.1A external-priority patent/GB9603147D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO983453D0 publication Critical patent/NO983453D0/no
Publication of NO983453L publication Critical patent/NO983453L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO983453A 1996-01-29 1998-07-27 Fremgangsmåte for ökning av sfinkterfunksjon NO983453L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1077196P 1996-01-29 1996-01-29
GBGB9603147.1A GB9603147D0 (en) 1996-02-15 1996-02-15 Methods of increasing sphincter competence
PCT/US1997/001159 WO1997026876A1 (en) 1996-01-29 1997-01-27 Methods of increasing sphincter competence

Publications (2)

Publication Number Publication Date
NO983453D0 NO983453D0 (no) 1998-07-27
NO983453L true NO983453L (no) 1998-09-11

Family

ID=26308706

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983453A NO983453L (no) 1996-01-29 1998-07-27 Fremgangsmåte for ökning av sfinkterfunksjon

Country Status (11)

Country Link
EP (1) EP0910378A4 (ru)
JP (1) JP2000503991A (ru)
CN (1) CN1213303A (ru)
AU (1) AU732473B2 (ru)
CZ (1) CZ235598A3 (ru)
EA (1) EA001103B1 (ru)
HU (1) HUP9903440A3 (ru)
IL (1) IL125522A0 (ru)
NO (1) NO983453L (ru)
NZ (1) NZ331085A (ru)
WO (1) WO1997026876A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
US6455568B2 (en) 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
US6376486B1 (en) 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
WO2002003989A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
MX2008014825A (es) 2006-05-22 2008-12-01 Hormos Medical Ltd Moduladores selectivos del receptor de estrogeno o inhibidores de aromatasa para tratar prostatitis cronica no bacteriana.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391557A (en) * 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
AU3899595A (en) * 1994-12-02 1996-06-19 Mostyn Farmer Golf stance training aid
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents

Also Published As

Publication number Publication date
NO983453D0 (no) 1998-07-27
CN1213303A (zh) 1999-04-07
EP0910378A1 (en) 1999-04-28
AU732473B2 (en) 2001-04-26
EA001103B1 (ru) 2000-10-30
IL125522A0 (en) 1999-03-12
WO1997026876A1 (en) 1997-07-31
JP2000503991A (ja) 2000-04-04
HUP9903440A3 (en) 2000-07-28
NZ331085A (en) 2000-06-23
EP0910378A4 (en) 1999-06-23
CZ235598A3 (cs) 1999-03-17
EA199800676A1 (ru) 1999-02-25
HUP9903440A2 (hu) 2000-06-28
AU1838697A (en) 1997-08-20

Similar Documents

Publication Publication Date Title
NO971520L (no) Fremgangsmåte for hemming av tilstander forbundet med neuropeptid Y
DK0664126T3 (da) Hæmning af trombin
GR3033269T3 (en) Methods of inhibiting viral replication
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
NO943878D0 (no) Hemming av uterinfibrose
NO970786L (no) Fremgangsmåte for hemming av benprotesedegradering
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
NO983453L (no) Fremgangsmåte for ökning av sfinkterfunksjon
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
NO981578L (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
NO971794L (no) Fremgangsmåte for hemming av tilstander forbundet med bradykinin
PH31620A (en) Benzothiophenes for bone healing and fracture repair.
NO970783L (no) Fremgangsmåte for å hindre endometrialkreft
DK0659414T3 (da) Inhibering af hirutisme og alopeci hos kvinder
MX9701333A (es) Metodos para inhibir el daño neuronal.
NO973103L (no) Fremgangsmåte for inhibering av veksthormoneffekter
DK0772438T3 (da) Anvendelse af benzothiophener til fremstilling af et medikament til reduktion af ardannelse under sårheling
DK0771201T3 (da) Anvendelse af 2-phenyl-3-aroylbenzothiophener til fremstilling af et medikament til inhibering af primær endometrisk hyperplasi
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application